News Sentiment

CRVS sentiment intelligence

Corvus Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.67 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+2.9% over one week, +31.3% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Corvus Pharmaceuticals (CRVS) Proxy filing Summary

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 2.9% Price confirming higher
Trend fit Trend inactive 31.3% over four weeks
Fair value 162.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 8
TradingView 7
simplywall.st 5
Sahm 4
TradingKey 4
Quartr 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 20
Analyst action 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Quartr Direct company coverage

Corvus Pharmaceuticals (CRVS) Proxy filing Summary

Corvus Pharmaceuticals (CRVS) has released its proxy filing summary, outlining key proposals for its upcoming virtual annual meeting on April 24, 2026. Shareholders will vote on the election of two Class I Directors, the ratification of PricewaterhouseCoopers LLP as the independe

Tone
Positive 70/100
Event
Market update
Published
11 Jul 2026 02:39
Source
Quartr
Quartr Direct company coverage

Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary

Corvus Pharmaceuticals (CRVS) reported an increase in Q4 2024 R&D expenses to $6M, primarily due to higher soquelitinib clinical trial costs, resulting in a net loss of $12.1M. The company's cash and equivalents totaled $52M, providing a financial runway into Q1 2026. Corvus is a

Tone
Positive 67/100
Event
Earnings
Published
09 Jul 2026 02:09
Source
Quartr
Quartr Direct company coverage

Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary

Corvus Pharmaceuticals reported on its Q1 2025 earnings, highlighting positive Phase I trial results for soquelitinib in atopic dermatitis and its advancement into multiple indications. The company's operational runway is extended into Q4 2026 due to warrant exercises, and it ant

Tone
Positive 72/100
Event
Earnings
Published
08 Jul 2026 14:10
Source
Quartr
Sahm Direct company coverage

Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump?

Corvus Pharmaceuticals (CRVS) has seen significant share price growth, with its stock closing at $13.05 and a market value of $1.09 billion. Despite this surge, a prevailing narrative suggests the company is 62.7% undervalued, with a fair value target of $35 given its potential i

Tone
Positive 72/100
Event
Analyst action
Published
28 Jun 2026 10:10
Source
Sahm
TradingView Direct company coverage

Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS)

This article provides an overview of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) stock, including its current price, performance, and analyst forecasts. It details financial data such as market capitalization, earnings per share, and revenue, as well as highlighting upcoming earn

Tone
Positive 67/100
Event
Earnings
Published
27 Jun 2026 15:11
Source
TradingView
TradingView Direct company coverage

Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17)

This article provides financial actuals and estimates for Corvus Pharmaceuticals, Inc. (C17) traded on the BX Swiss exchange. It details analyst price targets, upcoming earnings reports, past earnings and revenue figures, and company information including employee count and divid

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS

This article focuses on the enterprise value to revenue forward metric for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It appears to be a financial data point or analysis offered by TradingView, indicating a specific valuation multiple for the company. The content primarily high

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS

This article provides a brief financial data point regarding the "Price to sales forward" for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It appears to be an excerpt from a financial data platform, indicating the value and change for this metric, presented without additional det

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 11:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS

This article provides the "Price to book forward" financial metric for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It lists "Period," "Value," "Change," and "Change %" as data points, indicating financial performance. The content is brief and appears to be a data

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 05:42
Source
TradingView
TradingKey Direct company coverage

Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Corvus Pharmaceuticals Inc (CRVS), highlighting analyst ratings, price targets, and past and projected EPS. Based on ratings from 7 analysts, most recommend a "Buy" trend for CRVS, with a target price of USD 14.00 and an upside space

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 01:09
Source
TradingKey
TradingKey Direct company coverage

Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Corvus Pharmaceuticals Inc (CRVS), including its PE, PB, PS, and PCF ratios. However, the company has not yet disclosed the relevant data for these valuation metrics. The page also displays the current stock price, market capitalizat

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:09
Source
TradingKey
Sahm Direct company coverage

Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock

David Moore, an Independent Director at Corvus Pharmaceuticals, recently bought an additional US$250k worth of stock at US$11.53 per share, increasing his holdings. This transaction marks the largest insider purchase in the last twelve months, indicating continued confidence in t

Tone
Positive 70/100
Event
Market update
Published
17 Jun 2026 17:40
Source
Sahm
TradingKey Direct company coverage

Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Corvus Pharmaceuticals Inc (CRVS). It states that the company has distributed $0.00 in dividends over the past five years and reports "No Data" for both dividend payouts and stock splits, indicating no such

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 03:40
Source
TradingKey
TradingKey Direct company coverage

Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Corvus Pharmaceuticals Inc (CRVS) based on business segments and regional contributions. However, it indicates that the relevant financial data for such a breakdown has not been disclosed by the company. The

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 03:40
Source
TradingKey
Stock Titan Direct company coverage

[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity

Corvus Pharmaceuticals director Ian T. Clark received a grant of 15,000 stock options with an exercise price of $11.60 per share, expiring on June 11, 2036. These options represent compensation and will vest on the earlier of the first anniversary of the grant date or the company

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 07:09
Source
Stock Titan
Stock Titan Direct company coverage

Corvus (CRVS) director awarded options for 15,000 shares at $11.60

Corvus Pharmaceuticals director Richard van den Broek was granted options to purchase 15,000 shares of common stock at an exercise price of $11.60 per share. These options will vest in a single tranche on the earlier of one year from the grant date or the company's 2027 annual st

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 04:39
Source
Stock Titan
Stock Titan Direct company coverage

Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option

Corvus Pharmaceuticals director David Scott Moore purchased 21,700 shares of common stock at $11.5316 per share in an open-market transaction, increasing his direct holdings to 21,700 shares. Additionally, he was granted a stock option for 15,000 shares at an exercise price of $1

Tone
Positive 73/100
Event
Market update
Published
16 Jun 2026 04:09
Source
Stock Titan
Stock Titan Direct company coverage

Director at Corvus (CRVS) receives grant of 15,000 stock options

Corvus Pharmaceuticals director Peter A. Thompson has been granted 15,000 stock options with an exercise price of $11.60 and an expiration date of June 11, 2036. These options vest on the earlier of the first anniversary of the grant date or the 2027 annual stockholders’ meeting,

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options

Corvus Pharmaceuticals director Linda Grais was granted 15,000 stock options with an exercise price of $11.6000 per share, expiring on June 11, 2036. These options will vest and become exercisable 100% on the earlier of the first anniversary of the grant date or the company’s 202

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes

Corvus Pharmaceuticals (CRVS) has reported the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class I directors Richard A. Miller and Linda S. Grais, the ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and n

Tone
Neutral 50/100
Event
Earnings
Published
12 Jun 2026 19:40
Source
Stock Titan
Baystreet.ca Direct company coverage

Corvus Hikes on Position in Angel

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) announced its participation in a new $13.5 million financing round for its Chinese collaboration partner, Angel Pharmaceuticals Ltd. Corvus, already Angel Pharma's largest shareholder, is investing $5 million to support the development

Tone
Positive 66/100
Event
Market update
Published
10 Jun 2026 02:39
Source
Baystreet.ca
Finviz Direct company coverage

CRVS - Corvus Pharmaceuticals Inc Stock Price and Quote

This article provides a detailed stock overview for Corvus Pharmaceuticals Inc (CRVS), including its current stock price, financial metrics, analyst ratings, and recent news history. It lists key financial data such as market cap, income, sales, and employee count, alongside perf

Tone
Positive 72/100
Event
Analyst action
Published
09 Jun 2026 14:13
Source
Finviz
Market source Direct company coverage

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharmaceuticals announced an additional $5 million investment in its Chinese collaboration partner, Angel Pharmaceuticals, as part of a $13.5 million financing round. This funding will advance the clinical development of soquelitinib in China for atopic dermatitis and asth

Tone
Positive 71/100
Event
Market update
Published
09 Jun 2026 14:09
Source
Market source
Stock Titan Direct company coverage

$13.5M bet on soquelitinib: China eczema and asthma trials move ahead

Corvus Pharmaceuticals is investing $5 million in a new $13.5 million financing round for its China partner, Angel Pharmaceuticals. This investment will support the development of soquelitinib for atopic dermatitis and asthma in China, funding an ongoing Phase 1b/2 atopic dermati

Tone
Positive 71/100
Event
Market update
Published
09 Jun 2026 11:39
Source
Stock Titan